Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Number of holders
-
89
-
Total 13F shares, excl. options
-
65,498,777
-
Shares change
-
+9,639,950
-
Total reported value, excl. options
-
$887,959,093
-
Value change
-
+$131,556,420
-
Put/Call ratio
-
23%
-
Number of buys
-
32
-
Number of sells
-
-46
-
Price
-
$13.56
Significant Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q3 2018
106 filings reported holding ADAPY - Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share as of Q3 2018.
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) has 89 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 65,498,777 shares
of 1,571,428,571 outstanding shares and own 4.2% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (20,362,011 shares), NEA Management Company, LLC (15,832,611 shares), Capital World Investors (6,792,700 shares), BAILLIE GIFFORD & CO (3,417,627 shares), FMR LLC (2,243,825 shares), MILLENNIUM MANAGEMENT LLC (2,172,648 shares), WELLINGTON MANAGEMENT GROUP LLP (1,500,127 shares), RENAISSANCE TECHNOLOGIES LLC (1,033,800 shares), Balyasny Asset Management LLC (982,000 shares), and ORACLE INVESTMENT MANAGEMENT INC (897,494 shares).
This table shows the top 89 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.